CNTNAP2 (Q9UHC6) variants and mutations
CNTNAP2 (also known as Q9UHC6) is a human protein-coding gene encoding a contactin-associated protein-like 2 protein. It organizes specialized neuronal membrane domains and contributes to axonal development, synaptic connectivity, and clustering of potassium channels at juxtaparanodes. Biallelic loss-of-function variants can cause severe neurodevelopmental disease with epilepsy and language impairment, while heterozygous associations are more complex. This analysis covers 2,416 CNTNAP2 variants and mutations. Of these, 82% have computational variant effect predictions. Disease context includes cortical dysplasia-focal epilepsy syndrome, Cortical dysplasia - focal epilepsy syndrome, and Pitt-Hopkins-like syndrome. Example CNTNAP2 variants include Q2R, Q2K, and Q2*.
Variant analysis overview
- Gene: CNTNAP2
- Protein: Q9UHC6
- UniProt accession: Q9UHC6
- Organism: Homo sapiens
- Variants analyzed: 2416
- Variant scope: all variants
- Completed: 2026-08-19
Variant and mutation evidence
- Variant composition: 2,167 unspecified-consequence records; 145 missense variants; 6 stop-gained variants; 89 synonymous variants; 7 frameshift variants; 1 in-frame deletions; 1 splice-region variants
- Prediction scores: 1,982 variants have prediction scores (82% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: cortical dysplasia-focal epilepsy syndrome, Cortical dysplasia - focal epilepsy syndrome, Pitt-Hopkins-like syndrome, hereditary disease, Rolandic epilepsy, self-limited epilepsy with centrotemporal spikes, autism, alcohol drinking, mathematical ability, dislocation, stroke disorder, Alzheimer disease.
Protein structure and variant hotspots
- Protein features: 1 transmembrane segments; 8 domains; 14 post-translational modification sites.
- Structural context: 1,926 variants have structural context.
- PTM context: 25 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable CNTNAP2 variants
Examples include Q2R, Q2K, Q2*, Q2P, Q2L, Q2H, A3G, A3V. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- Q2R (p.Gln2Arg), rs1797490798, ClinGen CA369921982, ClinVar RCV001219582, Ensembl rs1797490798, REVEL 0.21, CADD 13.70, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- Q2K (p.Gln2Lys), gnomAD 7-146116880-C-A, REVEL 0.29, MetaLR 0.41
- Q2* (p.Gln2Ter), gnomAD 7-146116880-C-T, CADD 33.00
- Q2P (p.Gln2Pro), gnomAD 7-146116881-A-C, REVEL 0.20, MetaLR 0.40
- Q2L (p.Gln2Leu), gnomAD 7-146116881-A-T, REVEL 0.22, MetaLR 0.33
- Q2H (p.Gln2His), gnomAD 7-146116882-G-T, REVEL 0.15, MetaLR 0.42
- A3G (p.Ala3Gly), Ensembl rs2116710899, MetaLR 0.32, MetaSVM -0.70
- A3V (p.Ala3Val), NCI-TCGA TCGA novel, REVEL 0.18, CADD 2.91, Variant assessed as somatic; moderate impact.
- A3E (p.Ala3Glu), gnomAD 7-146116884-C-A, REVEL 0.23, MetaLR 0.33
- A3A (p.Ala3Ala), gnomAD 7-146116885-G-T, CADD 13.40
- A4G (p.Ala4Gly), Ensembl rs1584757090, MetaLR 0.37, MetaSVM -0.67
- A4V (p.Ala4Val), Ensembl rs1584757090, REVEL 0.16, CADD 16.20
- A4T (p.Ala4Thr), gnomAD 7-146116886-G-A, REVEL 0.10, MetaLR 0.39
- A4S (p.Ala4Ser), gnomAD 7-146116886-G-T, REVEL 0.16, MetaLR 0.39
- A4D (p.Ala4Asp), gnomAD 7-146116887-C-A, REVEL 0.23, MetaLR 0.37
- A4A (p.Ala4Ala), gnomAD 7-146116888-T-C, CADD 8.81
- P5L (p.Pro5Leu), rs779710846, ClinGen CA4545681, ClinVar RCV001938112, ExAC rs779710846, REVEL 0.22, CADD 14.70, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- P5S (p.Pro5Ser), rs1797490961, ClinGen CA369922000, ClinVar RCV001037731, Ensembl rs1797490961, REVEL 0.16, CADD 16.00, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- P5T (p.Pro5Thr), rs1797490961, ClinGen CA369921998, ClinVar RCV001367276, Ensembl rs1797490961, REVEL 0.14, CADD 15.10, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- P5P (p.Pro5Pro), rs1180036875, gnomAD 7-146116891-G-C, CADD 13.50
- R6C (p.Arg6Cys), NCI-TCGA TCGA novel, REVEL 0.34, CADD 23.10, Variant assessed as somatic; moderate impact.
- R6G (p.Arg6Gly), rs1584757095, ClinGen CA369922004, ClinVar RCV000803850, NCI-TCGA TCGA novel, REVEL 0.18, CADD 18.60, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- R6H (p.Arg6His), rs2116710944, ClinGen CA369922006, ClinVar RCV001757742, Ensembl rs2116710944, REVEL 0.21, CADD 23.10, Uncertain significance, not provided
- R6S (p.Arg6Ser), NCI-TCGA TCGA novel, REVEL 0.18, CADD 18.50, Variant assessed as somatic; moderate impact.
- R6L (p.Arg6Leu), gnomAD 7-146116893-G-T, REVEL 0.26, MetaLR 0.45
- R6R (p.Arg6Arg), rs748908765, gnomAD 7-146116894-C-A, CADD 8.61
- A7S (p.Ala7Ser), rs1064795189, ClinGen CA16618368, ClinVar RCV000487185, TOPMed rs1064795189, REVEL 0.14, CADD 13.80, Uncertain significance, not provided
- A7T (p.Ala7Thr), rs1064795189, TOPMed rs1064795189, REVEL 0.14, CADD 16.30, Uncertain significance
- A7D (p.Ala7Asp), gnomAD 7-146116896-C-A, REVEL 0.33, MetaLR 0.45
- A7V (p.Ala7Val), gnomAD 7-146116896-C-T, REVEL 0.19, MetaLR 0.40
- A7A (p.Ala7Ala), rs1380843777, gnomAD 7-146116897-C-G, CADD 14.40
- G8A (p.Gly8Ala), gnomAD 7-146116897-CG-C, CADD 26.10
- G8S (p.Gly8Ser), gnomAD 7-146116898-G-A, REVEL 0.17, MetaLR 0.33
- G8C (p.Gly8Cys), gnomAD 7-146116898-G-T, REVEL 0.39, MetaLR 0.51
- G8D (p.Gly8Asp), gnomAD 7-146116899-G-A, REVEL 0.43, MetaLR 0.45
- G8V (p.Gly8Val), gnomAD 7-146116899-G-T, REVEL 0.30, MetaLR 0.44
- G8G (p.Gly8Gly), rs1450013484, gnomAD 7-146116900-C-A, CADD 13.40
- C9R (p.Cys9Arg), gnomAD 7-146116901-T-C, REVEL 0.38, MetaLR 0.44
- C9G (p.Cys9Gly), gnomAD 7-146116901-T-G, REVEL 0.25, MetaLR 0.43
- C9F (p.Cys9Phe), gnomAD 7-146116902-G-T, REVEL 0.27, MetaLR 0.42
- C9C (p.Cys9Cys), rs1797491394, gnomAD 7-146116903-C-T, CADD 14.50
- C9* (p.Cys9Ter), gnomAD 7-146116903-C-A, CADD 37.00
- G10A (p.Gly10Ala), NCI-TCGA TCGA novel, REVEL 0.21, CADD 20.10, Variant assessed as somatic; moderate impact.
- G10E (p.Gly10Glu), rs886044541, ClinGen CA10606887, ClinVar RCV000331272, Ensembl rs886044541, REVEL 0.24, CADD 21.60, Uncertain significance, not provided
- G10W (p.Gly10Trp), gnomAD rs1169898267, REVEL 0.38, CADD 23.40
- A11Q (p.Ala11Gln), gnomAD 7-146116903-CG-C, CADD 24.90
- A11T (p.Ala11Thr), gnomAD 7-146116907-G-A, REVEL 0.40, MetaLR 0.64
- A11S (p.Ala11Ser), gnomAD 7-146116907-G-T, REVEL 0.44, MetaLR 0.65
- A11E (p.Ala11Glu), gnomAD 7-146116908-C-A, REVEL 0.49, MetaLR 0.64
- A11A (p.Ala11Ala), rs1368186066, gnomAD 7-146116909-A-G, CADD 15.40
- A12V (p.Ala12Val), rs2535699006, ClinGen CA369922043, ClinVar RCV002304658, NCI-TCGA TCGA novel, REVEL 0.22, CADD 18.10, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- A12S (p.Ala12Ser), gnomAD 7-146116910-G-T, REVEL 0.28, MetaLR 0.42
- A12T (p.Ala12Thr), gnomAD 7-146116910-G-A, REVEL 0.25, MetaLR 0.44
- A12E (p.Ala12Glu), gnomAD 7-146116911-C-A, REVEL 0.45, MetaLR 0.39
- A12A (p.Ala12Ala), rs1428678213, gnomAD 7-146116912-G-A, CADD 14.30
- L13F (p.Leu13Phe), rs796052375, ClinGen CA314118, ClinVar RCV000187183, ClinVar RCV000690704, REVEL 0.21, CADD 21.80, Uncertain significance, not provided; Inborn genetic diseases; Cortical dysplasia-focal epilepsy syndrom
- L13I (p.Leu13Ile), gnomAD 7-146116913-C-A, REVEL 0.15, MetaLR 0.40
- L13P (p.Leu13Pro), gnomAD 7-146116914-T-C, REVEL 0.59, MetaLR 0.43
- L13L (p.Leu13Leu), rs1017715989, gnomAD 7-146116915-C-G, CADD 3.90
- L14P (p.Leu14Pro), rs1283986677, ClinGen CA369922052, ClinVar RCV001216518, ClinVar RCV004690019, REVEL 0.26, CADD 6.72, Uncertain significance, Inborn genetic diseases; not specified; Cortical dysplasia-focal epilepsy syndro
- L14L (p.Leu14Leu), rs542709358, gnomAD 7-146116916-C-T, CADD 9.13
- L14M (p.Leu14Met), gnomAD 7-146116916-C-A, REVEL 0.18, MetaLR 0.43
- L15Q (p.Leu15Gln), Ensembl rs1797491896, REVEL 0.55, CADD 27.00
- L15V (p.Leu15Val), gnomAD 7-146116919-C-G, REVEL 0.22, MetaLR 0.38
- L15L (p.Leu15Leu), gnomAD 7-146116919-C-T, CADD 12.90
- L15M (p.Leu15Met), gnomAD 7-146116919-C-A, REVEL 0.26, MetaLR 0.64
- W16C (p.Trp16Cys), rs886044073, ClinGen CA10606315, ClinVar RCV000726271, ClinVar RCV001232345, REVEL 0.47, CADD 23.90, Uncertain significance, Inborn genetic diseases; not provided; Cortical dysplasia-focal epilepsy syndrom
- W16R (p.Trp16Arg), gnomAD 7-146116922-T-A, REVEL 0.53, MetaLR 0.42
- W16L (p.Trp16Leu), gnomAD 7-146116923-G-T, REVEL 0.30, MetaLR 0.33
- W16* (p.Trp16Ter), gnomAD 7-146116923-G-A, CADD 38.00
- I17L (p.Ile17Leu), gnomAD rs982512594, REVEL 0.21, CADD 14.90
- I17V (p.Ile17Val), gnomAD 7-146116925-A-G, REVEL 0.17, MetaLR 0.40
- I17F (p.Ile17Phe), gnomAD 7-146116925-A-T, REVEL 0.26, MetaLR 0.46
- I17N (p.Ile17Asn), gnomAD 7-146116926-T-A, REVEL 0.33, MetaLR 0.46
- I17T (p.Ile17Thr), gnomAD 7-146116926-T-C, REVEL 0.28, MetaLR 0.51
- I17I (p.Ile17Ile), gnomAD 7-146116927-T-A, CADD 5.97
- V18F (p.Val18Phe), gnomAD 7-146116928-G-T, REVEL 0.23, MetaLR 0.36
- V18I (p.Val18Ile), gnomAD 7-146116928-G-A, REVEL 0.14, MetaLR 0.39
- V18A (p.Val18Ala), gnomAD 7-146116929-T-C, REVEL 0.20, MetaLR 0.42
- V18G (p.Val18Gly), gnomAD 7-146116929-T-G, REVEL 0.31, MetaLR 0.38
- V18V (p.Val18Val), gnomAD 7-146116930-C-G, CADD 12.80
- S19G (p.Ser19Gly), rs1797492098, ClinGen CA369922081, ClinVar RCV001336153, Ensembl rs1797492098, REVEL 0.23, CADD 15.50, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- S19T (p.Ser19Thr), rs1064794501, ClinGen CA16618369, ClinVar RCV000480461, Ensembl rs1064794501, AlphaMissense 0.10, MetaLR 0.43, Uncertain significance, not provided
- S19R (p.Ser19Arg), gnomAD 7-146116931-A-C, REVEL 0.36, MetaLR 0.35
- S19C (p.Ser19Cys), gnomAD 7-146116931-A-T, REVEL 0.28, MetaLR 0.42
- S19N (p.Ser19Asn), gnomAD 7-146116932-G-A, REVEL 0.35, MetaLR 0.41
- S19S (p.Ser19Ser), rs1584757130, gnomAD 7-146116933-C-T, CADD 14.40
- S20N (p.Ser20Asn), Ensembl rs886062048, REVEL 0.32, CADD 21.30, Uncertain significance
- S20G (p.Ser20Gly), gnomAD 7-146116934-A-G, REVEL 0.18, MetaLR 0.35
- S20I (p.Ser20Ile), gnomAD 7-146116935-G-T, REVEL 0.35, MetaLR 0.44
- S20T (p.Ser20Thr), gnomAD 7-146116935-G-C, REVEL 0.26, MetaLR 0.43
- S20R (p.Ser20Arg), gnomAD 7-146116936-C-A, REVEL 0.41, MetaLR 0.44
- S20S (p.Ser20Ser), gnomAD 7-146116936-C-T, CADD 13.30
- C21R (p.Cys21Arg), gnomAD rs1295468688, REVEL 0.26, CADD 4.19
- C21Y (p.Cys21Tyr), rs1341597305, ClinGen CA369922097, ClinVar RCV002028724, ClinVar RCV002657716, REVEL 0.29, CADD 9.00, Uncertain significance, Inborn genetic diseases; Cortical dysplasia-focal epilepsy syndrome
- C21F (p.Cys21Phe), gnomAD 7-146116938-G-T, REVEL 0.24, MetaLR 0.41
- C21C (p.Cys21Cys), gnomAD 7-146116939-C-T, CADD 13.20
- L22P (p.Leu22Pro), rs768374052, ClinGen CA314255, ClinVar RCV000472018, ClinVar RCV000726104, REVEL 0.28, CADD 23.00, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome; not provided; Inborn genetic disease
- L22S (p.Leu22Ser), gnomAD 7-146116938-GC-G, CADD 24.10
- L22I (p.Leu22Ile), gnomAD 7-146116940-C-A, REVEL 0.21, MetaLR 0.40
- L22L (p.Leu22Leu), gnomAD 7-146116942-C-T, CADD 13.40
- C23R (p.Cys23Arg), gnomAD 7-146116943-T-C, REVEL 0.51, MetaLR 0.45
- C23F (p.Cys23Phe), gnomAD 7-146116944-G-T, REVEL 0.50, MetaLR 0.42
- C23Y (p.Cys23Tyr), gnomAD 7-146116944-G-A, REVEL 0.52, MetaLR 0.44
- C23* (p.Cys23Ter), gnomAD 7-146116945-C-A, CADD 37.00
- R24G (p.Arg24Gly), gnomAD 7-146116946-A-G, REVEL 0.45, MetaLR 0.40
- R24I (p.Arg24Ile), gnomAD 7-146116947-G-T, REVEL 0.40, MetaLR 0.44
- A25T (p.Ala25Thr), rs200866893, ClinGen CA233775, ClinVar RCV000513738, ClinVar RCV000764694, REVEL 0.29, CADD 22.00, Conflicting interpretations, Inborn genetic diseases; not specified; not provided
- A25S (p.Ala25Ser), gnomAD 7-146116949-G-T, REVEL 0.23, MetaLR 0.45
- A25D (p.Ala25Asp), gnomAD 7-146116950-C-A, REVEL 0.49, MetaLR 0.48
- A25V (p.Ala25Val), gnomAD 7-146116950-C-T, REVEL 0.40, MetaLR 0.45
- A25A (p.Ala25Ala), gnomAD 7-146116951-C-T, CADD 15.60
- W26* (p.Trp26Ter), gnomAD rs1440926389, CADD 43.00
- W26R (p.Trp26Arg), gnomAD 7-146116952-T-C, REVEL 0.24, MetaLR 0.27
- W26S (p.Trp26Ser), gnomAD 7-146116953-G-C, REVEL 0.33, MetaLR 0.43
- W26L (p.Trp26Leu), gnomAD 7-146116953-G-T, REVEL 0.24, MetaLR 0.41
- W26C (p.Trp26Cys), gnomAD 7-146116954-G-T, REVEL 0.46, MetaLR 0.50
- T27S (p.Thr27Ser), gnomAD 7-146116955-A-T, REVEL 0.20, MetaLR 0.40
- T27A (p.Thr27Ala), gnomAD 7-146116955-A-G, REVEL 0.25, MetaLR 0.39
- T27K (p.Thr27Lys), gnomAD 7-146116956-C-A, REVEL 0.44, MetaLR 0.45
- T27M (p.Thr27Met), gnomAD 7-146116956-C-T, REVEL 0.41, MetaLR 0.45
- T27T (p.Thr27Thr), gnomAD 7-146116957-G-C, CADD 10.80
- A28P (p.Ala28Pro), TOPMed rs978368135
- A28V (p.Ala28Val), rs796052366, ClinGen CA314068, ClinVar RCV000187150, Ensembl rs796052366, AlphaMissense 0.10, MetaLR 0.46, Likely benign, not specified
- A28S (p.Ala28Ser), gnomAD 7-146116958-G-T, REVEL 0.18, MetaLR 0.46
- A28T (p.Ala28Thr), gnomAD 7-146116958-G-A, REVEL 0.18, MetaLR 0.47
- A28D (p.Ala28Asp), gnomAD 7-146116959-C-A, REVEL 0.41, MetaLR 0.42
- P29S (p.Pro29Ser), NCI-TCGA Cosmic COSV6222, REVEL 0.13, CADD 16.80, Variant assessed as somatic; moderate impact.
- P29P (p.Pro29Pro), rs886062049, gnomAD 7-146116963-C-T, CADD 12.70
- S30C (p.Ser30Cys), rs2535699142, ClinGen CA369922156, ClinVar RCV003032784, REVEL 0.24, CADD 21.20, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- S30T (p.Ser30Thr), gnomAD rs1465250562, REVEL 0.16, CADD 12.60, Uncertain significance, Inborn genetic diseases
- S30P (p.Ser30Pro), gnomAD 7-146116964-T-C, REVEL 0.21, MetaLR 0.29
- S30Y (p.Ser30Tyr), gnomAD 7-146116965-C-A, REVEL 0.20, MetaLR 0.42
- S30S (p.Ser30Ser), rs572889297, gnomAD 7-146116966-C-T, CADD 10.70
- T31R (p.Thr31Arg), rs1387747328, ClinGen CA369922163, ClinVar RCV001952986, TOPMed rs1387747328, REVEL 0.20, CADD 22.20, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- T31K (p.Thr31Lys), gnomAD 7-146116968-C-A, REVEL 0.19, MetaLR 0.46
- T31M (p.Thr31Met), gnomAD 7-146116968-C-T, REVEL 0.20, MetaLR 0.46
- T31T (p.Thr31Thr), gnomAD 7-146116969-G-A, CADD 12.80
- S32C (p.Ser32Cys), ExAC rs748064330, gnomAD rs748064330, REVEL 0.27, CADD 23.30
- S32T (p.Ser32Thr), gnomAD 7-146116970-T-A, REVEL 0.14, MetaLR 0.45
- S32F (p.Ser32Phe), gnomAD 7-146116971-C-T, REVEL 0.21, MetaLR 0.44
- S32Y (p.Ser32Tyr), gnomAD 7-146116971-C-A, REVEL 0.32, MetaLR 0.45
- Q33* (p.Gln33Ter), TOPMed rs794726938, gnomAD rs794726938, CADD 41.00, Uncertain significance
- Q33E (p.Gln33Glu), rs794726938, ClinGen CA369922169, ClinVar RCV003043193, TOPMed rs794726938, REVEL 0.26, CADD 19.40, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- Q33K (p.Gln33Lys), rs794726938, ClinGen CA238892, ClinVar RCV000173436, TOPMed rs794726938, REVEL 0.26, CADD 21.40, Uncertain significance, not provided
- Q33R (p.Gln33Arg), rs2129185951, ClinGen CA369922219, ClinVar RCV001774898, Ensembl rs2129185951, AlphaMissense 0.10, MetaLR 0.43, Uncertain significance, not provided
- K34* (p.Lys34Ter), NCI-TCGA Cosmic COSV1006, NCI-TCGA Cosmic COSV6218, Variant assessed as somatic; high impact.
- K34E (p.Lys34Glu), NCI-TCGA Cosmic COSV1006, NCI-TCGA Cosmic COSV6218, MetaLR 0.38, MetaSVM -0.42, Variant assessed as somatic; moderate impact.
- K34N (p.Lys34Asn), rs779436784, NCI-TCGA Cosmic COSV6219, ClinGen CA4545698, ClinVar RCV001349854, REVEL 0.20, CADD 15.10, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- K34K (p.Lys34Lys), rs779436784, gnomAD 7-146774275-A-G, CADD 8.47
- C35R (p.Cys35Arg), rs753486205, ClinGen CA4545699, ClinVar RCV001058449, ExAC rs753486205, REVEL 0.91, CADD 26.70, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- C35Y (p.Cys35Tyr), ExAC rs754683222, gnomAD rs754683222, MetaLR 0.93, MetaSVM 1.07
- C35C (p.Cys35Cys), gnomAD 7-146774278-T-C, CADD 8.28
- D36V (p.Asp36Val), ESP rs371991891, TOPMed rs371991891, gnomAD rs371991891, REVEL 0.76, CADD 27.10
- D36N (p.Asp36Asn), gnomAD 7-146774279-G-A, REVEL 0.40, MetaLR 0.59
- D36Y (p.Asp36Tyr), gnomAD 7-146774279-G-T, REVEL 0.71, MetaLR 0.79
- D36E (p.Asp36Glu), gnomAD 7-146774281-T-G, REVEL 0.47, MetaLR 0.48
- D36D (p.Asp36Asp), gnomAD 7-146774281-T-C, CADD 5.52
- E37K (p.Glu37Lys), NCI-TCGA Cosmic COSV6215, MetaLR 0.48, MetaSVM -0.07, Variant assessed as somatic; moderate impact.
- E37G (p.Glu37Gly), gnomAD 7-146774283-A-G, REVEL 0.44, MetaLR 0.42
- P38A (p.Pro38Ala), rs2129185957, ClinGen CA369922251, NCI-TCGA Cosmic COSV1006, ClinVar RCV001753360, AlphaMissense 0.21, MetaLR 0.62, Uncertain significance, not provided
- P38Q (p.Pro38Gln), NCI-TCGA Cosmic COSV1006, Variant assessed as somatic; moderate impact.
- P38S (p.Pro38Ser), rs2129185957, ClinGen CA369922252, NCI-TCGA Cosmic COSV1006, ClinVar RCV001996504, AlphaMissense 0.21, MetaLR 0.62, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- P38T (p.Pro38Thr), NCI-TCGA Cosmic COSV1006, MetaLR 0.65, MetaSVM 0.33, Variant assessed as somatic; moderate impact.
- P38L (p.Pro38Leu), gnomAD 7-146774286-C-T, REVEL 0.42, MetaLR 0.75
- P38P (p.Pro38Pro), rs778648331, gnomAD 7-146774287-A-G, CADD 0.10
- L39F (p.Leu39Phe), rs747896321, ClinGen CA314224, ClinVar RCV000187242, ClinVar RCV001857607, REVEL 0.53, CADD 23.50, Uncertain significance, not provided; Cortical dysplasia-focal epilepsy syndrome; Inborn genetic disease
- L39L (p.Leu39Leu), gnomAD 7-146774290-T-C, CADD 0.05
- S41F (p.Ser41Phe), rs1563225193, ClinGen CA369922272, ClinVar RCV001323632, gnomAD rs1563225193, REVEL 0.49, CADD 22.70, Uncertain significance, Cortical dysplasia-focal epilepsy syndrome
- S41Y (p.Ser41Tyr), gnomAD 7-146774295-C-A, REVEL 0.55, MetaLR 0.66
- S41S (p.Ser41Ser), gnomAD 7-146774296-T-A, CADD 1.94
- G42E (p.Gly42Glu), rs771874359, ExAC rs771874359, gnomAD rs771874359, REVEL 0.22, CADD 18.30, Variant assessed as somatic; moderate impact.
- L43F (p.Leu43Phe), gnomAD rs1289290635, REVEL 0.70, CADD 22.50, Uncertain significance, Inborn genetic diseases
- L43R (p.Leu43Arg), rs2485547309, ClinGen CA369922283, ClinVar RCV003614755, ClinVar RCV004765944, Uncertain significance, not provided; Cortical dysplasia-focal epilepsy syndrome
- L43I (p.Leu43Ile), gnomAD 7-146774300-C-A, REVEL 0.62, MetaLR 0.82
- L43L (p.Leu43Leu), rs777706230, gnomAD 7-146774302-C-T, CADD 2.32
- P44L (p.Pro44Leu), NCI-TCGA Cosmic COSV6216, NCI-TCGA Cosmic COSV6226, Variant assessed as somatic; moderate impact.
- P44R (p.Pro44Arg), NCI-TCGA Cosmic COSV6216, NCI-TCGA Cosmic COSV6226, TOPMed rs1802349423, REVEL 0.76, CADD 23.10, Uncertain significance, not specified
- P44T (p.Pro44Thr), NCI-TCGA Cosmic COSV6217, MetaLR 0.87, MetaSVM 0.72, Variant assessed as somatic; moderate impact.
- P44del (p.Pro44del), gnomAD 7-146774301-TCCC-, CADD 14.10
Public CNTNAP2 analysis runs
- CNTNAP2 analysis run — CNTNAP2 (2,416 variants) — completed 2026-08-19